August 12, 2013 8:33 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Perrigo Company (NYSE: PRGO) today announced the launch of the generic equivalent to Temodar®(temozolomide). Teva will manufacture, market and distribute the product inthe U.S. and both companies will equally share in the cost and profitabilityof the product in the U.S. Teva was first to file, making the product eligiblefor 180 days of marketing exclusivity.This product is the generic equivalent to Temodar® (temozolomide), indicatedfor the treatment of adult patients with newly diagnosed glioblastomamultiforme concomitantly with radiotherapy and then as maintenance treatmentand refractory anaplastic astrocytoma patients who have experienced diseaseprogression on a drug regimen containing nitrosourea and procarbazine.Temodar® had annual sales of approximately $423 million in the United States,according to IMS data as of December 31, 2012. The launch of this productprovides a quality alternative, making cancer therapy more cost effective forpatients who suffer from this devastating cancer.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.